The European venture firm raised 500 million euros, or about $579 million, for its latest fund, which follows a flurry of ...
Korro’s lead program for alpha-1 antitrypsin deficiency wasn’t as potent as anticipated, leading the company to change course ...
After multiple clinical setbacks and layoff rounds, Mersana accepted an offer in which the bulk of the payouts will only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback